Novel correlates of protection against pandemic H1N1 influenza A virus infection.
Adolescent
Adult
Aged
Antibodies, Viral
/ blood
Child
Child, Preschool
Cohort Studies
Female
Hemagglutination Inhibition Tests
Hemagglutinin Glycoproteins, Influenza Virus
/ immunology
Humans
Infant
Infant, Newborn
Influenza A Virus, H1N1 Subtype
/ immunology
Influenza, Human
/ epidemiology
Male
Middle Aged
Nicaragua
/ epidemiology
Pandemics
/ prevention & control
Young Adult
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
16
10
2018
accepted:
15
04
2019
pubmed:
5
6
2019
medline:
16
7
2019
entrez:
5
6
2019
Statut:
ppublish
Résumé
Influenza viruses remain a severe threat to human health, causing up to 650,000 deaths annually
Identifiants
pubmed: 31160818
doi: 10.1038/s41591-019-0463-x
pii: 10.1038/s41591-019-0463-x
pmc: PMC6608747
mid: NIHMS1527101
doi:
Substances chimiques
Antibodies, Viral
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
962-967Subventions
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400008C
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI120997
Pays : United States
Références
Nair, H. et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 378, 1917–1930 (2011).
doi: 10.1016/S0140-6736(11)61051-9
Thompson, W. W. et al. Estimates of US influenza-associated deaths made using four different methods. Influenza Other Respir. Viruses 3, 37–49 (2009).
doi: 10.1111/j.1750-2659.2009.00073.x
Nachbagauer, R. & Krammer, F. Universal influenza virus vaccines and therapeutic antibodies. Clin. Microbiol. Infect. 23, 222–228 (2017).
doi: 10.1016/j.cmi.2017.02.009
Jacobsen, H. et al. Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model. MBio 8, e01463-17 (2017).
doi: 10.1128/mBio.01463-17
Nachbagauer, R. et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines 2, 26 (2017).
doi: 10.1038/s41541-017-0026-4
Nachbagauer, R. & Palese, P. Development of next generation hemagglutinin-based broadly protective influenza virus vaccines. Curr. Opin. Immunol. 53, 51–57 (2018).
doi: 10.1016/j.coi.2018.04.001
Hobson, D., Curry, R. L., Beare, A. S. & Ward-Gardner, A. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses. J. Hyg. (Lond.) 70, 767–777 (1972).
Ohmit, S. E., Petrie, J. G., Cross, R. T., Johnson, E. & Monto, A. S. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J. Infect. Dis. 204, 1879–1885 (2011).
doi: 10.1093/infdis/jir661
Potter, C. W. & Oxford, J. S. Determinants of immunity to influenza infection in man. Br. Med. Bull. 35, 69–75 (1979).
doi: 10.1093/oxfordjournals.bmb.a071545
Erbelding, E. J. et al. A universal influenza vaccine: the strategic plan for the national institute of allergy and infectious diseases. J. Infect. Dis. 218, 347–354 (2018).
doi: 10.1093/infdis/jiy103
McElhaney, J. E., Coler, R. N. & Baldwin, S. L. Immunologic correlates of protection and potential role for adjuvants to improve influenza vaccines in older adults. Expert Rev. Vaccines 12, 759–766 (2013).
doi: 10.1586/14760584.2013.811193
Monto, A. S. et al. Antibody to influenza virus neuraminidase: an independent correlate of protection. J. Infect. Dis. 212, 1191–1199 (2015).
doi: 10.1093/infdis/jiv195
Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med. 19, 1305–1312 (2013).
doi: 10.1038/nm.3350
Coudeville, L. et al. Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model. BMC Med. Res. Methodol. 10, 18 (2010).
doi: 10.1186/1471-2288-10-18
Cauchemez, S. et al. Influenza infection rates, measurement errors and the interpretation of paired serology. PLoS Pathog. 8, e1003061 (2012).
doi: 10.1371/journal.ppat.1003061
Chen, Y.-Q. et al. Influenza infection in humans induces broadly cross-reactive and protective neuraminidase-reactive antibodies. Cell 173, 417–429.e10 (2018).
doi: 10.1016/j.cell.2018.03.030
Rajendran, M. et al. Analysis of anti-influenza virus neuraminidase antibodies in children, adults, and the elderly by ELISA and enzyme inhibition: evidence for original antigenic sin. MBio 8, e02281-16 (2017).
doi: 10.1128/mBio.02281-16
Babu, T. M. et al. Population serologic immunity to human and avian H2N2 viruses in the United States and Hong Kong for pandemic risk assessment. J. Infect. Dis. 218, 1054–1060 (2018).
doi: 10.1093/infdis/jiy291
Zost, S. J. et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc. Natl Acad. Sci. USA 114, 12578–12583 (2017).
doi: 10.1073/pnas.1712377114
de Vries, R. D. et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine 35, 238–247 (2017).
doi: 10.1016/j.vaccine.2016.11.082
DiLillo, D. J., Tan, G. S., Palese, P. & Ravetch, J. V. Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat. Med. 20, 143–151 (2014).
doi: 10.1038/nm.3443
Park, J. K. et al. Evaluation of preexisting anti-hemagglutinin stalk antibody as a correlate of protection in a healthy volunteer challenge with influenza A/H1N1pdm virus. MBio 9, e02284-17 (2018).
doi: 10.1128/mBio.02284-17
Varble, A. et al. Influenza A virus transmission bottlenecks are defined by infection route and recipient host. Cell Host Microbe 16, 691–700 (2014).
doi: 10.1016/j.chom.2014.09.020
Ng, S. et al. Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J. Infect. Dis. 208, 1320–1324 (2013).
doi: 10.1093/infdis/jit372
He, W. et al. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones. J. Virol. 89, 3610–3618 (2015).
doi: 10.1128/JVI.03099-14
Couch, R. B. et al. Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J. Infect. Dis. 207, 974–981 (2013).
doi: 10.1093/infdis/jis935
Chen, Y. Q., Lan, L. Y., Huang, M., Henry, C. & Wilson, P. C. Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance. J. Virol. 93, e01526–18 (2018).
Kosik, I. et al. Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies. J. Exp. Med. 216, 304–316 (2019).
pubmed: 30683737
pmcid: 6363425
Wohlbold, T. J. et al. Hemagglutinin stalk- and neuraminidase-specific monoclonal antibodies protect against lethal H10N8 influenza virus infection in mice. J. Virol. 90, 851–861 (2015).
doi: 10.1128/JVI.02275-15
Plotkin, S. A. Correlates of protection induced by vaccination. Clin. Vaccine Immunol. 17, 1055–1065 (2010).
doi: 10.1128/CVI.00131-10
Ekiert, D. C. et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489, 526–532 (2012).
doi: 10.1038/nature11414
Lee, J. et al. Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. Nat. Med. 22, 1456–1464 (2016).
doi: 10.1038/nm.4224
Paules, C. I., Marston, H. D., Eisinger, R. W., Baltimore, D. & Fauci, A. S. The pathway to a universal influenza vaccine. Immunity 47, 599–603 (2017).
doi: 10.1016/j.immuni.2017.09.007
Paules, C. I., Sullivan, S. G., Subbarao, K. & Fauci, A. S. Chasing seasonal influenza: the need for a universal influenza vaccine. N. Engl. J. Med. 378, 7–9 (2018).
doi: 10.1056/NEJMp1714916
Ng, S. et al. The timeline of influenza virus shedding in children and adults in a household transmission study of influenza in Managua, Nicaragua. Pediatr. Infect. Dis. J. 35, 583–586 (2016).
doi: 10.1097/INF.0000000000001083
Ng, S. et al. Association between haemagglutination inhibiting antibodies and protection against clade 6B viruses in 2013 and 2015. Vaccine 35, 6202–6207 (2017).
doi: 10.1016/j.vaccine.2017.09.036
Massingale, S. et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N. Engl. J. Med. 360, 2605–2615 (2009).
doi: 10.1056/NEJMoa0903810
WHO Global Influenza Surveillance Network. Manual for the Laboratory Diagnosis and Virological Surveillance of Influenza (World Health Organization, 2011).
Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp. 6, e51112 (2013).
Wohlbold, T. J. et al. Vaccination with adjuvanted recombinant neuraminidase induces broad heterologous, but not heterosubtypic, cross-protection against influenza virus infection in mice. MBio 6, e02556 (2015).
doi: 10.1128/mBio.02556-14
Roush, S. W. et al. (eds) M anual for the Surveillance of Vaccine-preventable Diseases (Centers for Disease Control and Prevention, 2008).
Benjamini, Y., Krieger, A. M. & Yekutieli, D. Adaptive linear step-up procedures that control the false discovery rate. Biometrika 93, 491–507 (2006).
doi: 10.1093/biomet/93.3.491